Kimberly-Clark Corporation (KMB) faced a challenging first quarter in 2025. While earnings per share exceeded expectations at
$1.93, reported revenue of
$4.8 billion missed estimated targets. The company's
organic sales also dipped by 1.6%. Increased supply chain costs, anticipated to have a $300 million impact, coupled with pressure from tariffs contributed to the disappointing results, prompting a revision of the FY25 outlook. Despite the challenges, Kimberly-Clark continued to implement
strategic innovations internally, targeting long-term growth. Its consistent dividend play remains attractive for investors seeking reliable returns. In other developments, Kimberly-Clark is contemplating selling its
international tissue business, with final bids around $4 billion under consideration. This move invites potential future M&A opportunities.
Jim Cramer remains positive about the stock, suggesting it could still perform well.
Kimberly-Clark Corp KMB News Analytics from Tue, 22 Oct 2024 07:00:00 GMT to Fri, 25 Apr 2025 20:48:45 GMT -
Rating 0
- Innovation 0
- Information 0
- Rumor -5
